Syndax Pharmaceuticals (SNDX) Change in Acquisitions & Divestments (2015 - 2026)

Syndax Pharmaceuticals' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $77.8 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 25.7% year-over-year to $77.8 million; the TTM figure through Mar 2026 stood at $459.1 million (up 22.77% YoY), while the FY2025 annual figure was $486.0 million, up 44.1% from the prior year.
• Change in Acquisitions & Divestments was $77.8 million for Q1 2026 at Syndax Pharmaceuticals, down from $144.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $154.9 million in Q2 2023 to a low of $50.4 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $99.0 million across 5 years, with a median of $103.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Change in Acquisitions & Divestments soared 149.45% in 2022, then tumbled 60.14% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $113.2 million in 2022, then fell by 0.22% to $113.0 million in 2023, then declined by 5.01% to $107.3 million in 2024, then surged by 34.85% to $144.8 million in 2025, then plunged by 46.27% to $77.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $77.8 million (Q1 2026), $144.8 million (Q4 2025), and $103.0 million (Q3 2025), per Business Quant data.